Gain Therapeutics Archives · BioBuzz

Loading …

Gain Raises $40 Million in IPO, Funds Will Advance Rare Disease Pipeline

<img width="300" height="300" alt="" data-srcset="https://biobuzz.io/wp-content/uploads/2021/03/Eric-Richman-300x300.jpg 300w, https://biobuzz.io/wp-content/uploads/2021/03/Eric-Richman-150x150.jpg 150w, https://biobuzz.io/wp-content/uploads/2021/03/Eric-Richman-75x75.jpg 75w" data-src="https://biobuzz.io/wp-content/uploads/2021/03/Eric-Richman-300x300.jpg" data-sizes="(max-width: 300px) 100vw, 300px" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="300" height="300" src="https://biobuzz.io/wp-content/uploads/2021/03/Eric-Richman-300x300.jpg" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload" alt="" srcset="https://biobuzz.io/wp-content/uploads/2021/03/Eric-Richman-300x300.jpg 300w, https://biobuzz.io/wp-content/uploads/2021/03/Eric-Richman-150x150.jpg 150w, https://biobuzz.io/wp-content/uploads/2021/03/Eric-Richman-75x75.jpg 75w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : March 19, 2021March 19, 2021 Published by : Alex Keown

Gain Therapeutics made its debut on the Nasdaq Thursday with a $40 million initial public offering. The company will use the funds to advance the development of its pipeline of therapeutics for rare genetic diseases characterized by protein misfolding.

Bethesda’s Gain Therapeutics Announces Pricing of IPO of Common Stock

<img width="300" height="300" alt="" data-srcset="https://biobuzz.io/wp-content/uploads/2021/03/Gain-300x300.jpg 300w, https://biobuzz.io/wp-content/uploads/2021/03/Gain-150x150.jpg 150w, https://biobuzz.io/wp-content/uploads/2021/03/Gain-75x75.jpg 75w" data-src="https://biobuzz.io/wp-content/uploads/2021/03/Gain-300x300.jpg" data-sizes="(max-width: 300px) 100vw, 300px" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="300" height="300" src="https://biobuzz.io/wp-content/uploads/2021/03/Gain-300x300.jpg" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload" alt="" srcset="https://biobuzz.io/wp-content/uploads/2021/03/Gain-300x300.jpg 300w, https://biobuzz.io/wp-content/uploads/2021/03/Gain-150x150.jpg 150w, https://biobuzz.io/wp-content/uploads/2021/03/Gain-75x75.jpg 75w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : March 18, 2021March 18, 2021 Published by : BioBuzz Media

Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock BETHESDA, Md., March 18, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial [….]

Gain Therapeutics and UMSOM Partner to Investigate Small Molecule Drugs

<img width="300" height="300" alt="" data-srcset="https://biobuzz.io/wp-content/uploads/2020/12/GAIN-300x300.png 300w, https://biobuzz.io/wp-content/uploads/2020/12/GAIN-150x150.png 150w, https://biobuzz.io/wp-content/uploads/2020/12/GAIN-75x75.png 75w" data-src="https://biobuzz.io/wp-content/uploads/2020/12/GAIN-300x300.png" data-sizes="(max-width: 300px) 100vw, 300px" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="300" height="300" src="https://biobuzz.io/wp-content/uploads/2020/12/GAIN-300x300.png" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload" alt="" srcset="https://biobuzz.io/wp-content/uploads/2020/12/GAIN-300x300.png 300w, https://biobuzz.io/wp-content/uploads/2020/12/GAIN-150x150.png 150w, https://biobuzz.io/wp-content/uploads/2020/12/GAIN-75x75.png 75w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : December 8, 2020December 8, 2020 Published by : Alex Keown

Gain Therapeutics and the University of Maryland School of Medicine forged a research collaboration to investigate Gain’s structurally targeted allosteric regulators (STARs) in cellular models of neuronopathic Gaucher disease (nGD) and Parkinson’s disease (PD).